Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ABEO

ABEO - Abeona Therapeutics Inc Stock Price, Fair Value and News

$4.84-0.27 (-5.28%)
Market Closed

17/100

ABEO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

17/100

ABEO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.13

Target 3M

$4.64

Target 6M

$4.39

ABEO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABEO Price Action

Last 7 days

-8.8%

Last 30 days

-9.9%

Last 90 days

-4.7%

Trailing 12 Months

-10.5%

ABEO RSI Chart

ABEO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABEO Valuation

Market Cap

262.3M

Price/Earnings (Trailing)

3.19

Price/Sales (Trailing)

75.18

EV/EBITDA

2.18

Price/Free Cashflow

-3.18

ABEO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.13

Target 3M

$4.64

Target 6M

$4.39

ABEO Fundamentals

ABEO Revenue

Revenue (TTM)

3.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ABEO Earnings

Earnings (TTM)

82.3M

Earnings Growth (Yr)

82.95%

Earnings Growth (Qtr)

-104.74%

ABEO Profitability

EBT Margin

2273.65%

Return on Equity

48.09%

Return on Assets

35.63%

Free Cashflow Yield

-31.4%

ABEO Investor Care

Shares Dilution (1Y)

24.66%

Diluted EPS (TTM)

1.55

ABEO Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
202304.6M3.6M3.6M
20221.7M1.6M1.5M1.4M
20210001.8M
20200010.0M12.2M
20186.9M7.5M9.0M9.3M
20171.0M843.0K878.0K837.0K
20161.3M1.4M1.5M1.1M
2015358.9K672.8K986.6K1.3M
20141.0M806.0K853.0K45.0K
20133.8M3.6M2.9M2.0M
20123.5M4.1M3.9M4.4M
20112.0M1.9M1.9M1.8M
20100002.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Abeona Therapeutics Inc

ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
 CEO
 WEBSITEabeonatherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES57

Abeona Therapeutics Inc Frequently Asked Questions

ABEO is the stock ticker symbol of Abeona Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Abeona Therapeutics Inc is 262.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ABEO's fair value in chart for subscribers.

The fair value guage provides a quick view whether ABEO is over valued or under valued. Whether Abeona Therapeutics Inc is cheap or expensive depends on the assumptions which impact Abeona Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABEO.

As of Wed Jan 28 2026, ABEO's PE ratio (Price to Earnings) is 3.19 and Price to Sales (PS) ratio is 75.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABEO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Abeona Therapeutics Inc has provided -0.229 (multiply by 100 for percentage) rate of return.